TY - JOUR
TI - Elevated Serum α-Synuclein Levels in Huntington's Disease Patients
AU - Breza, M.
AU - Emmanouilidou, E.
AU - Leandrou, E.
AU - Kartanou, C.
AU - Bougea, A.
AU - Panas, M.
AU - Stefanis, L.
AU - Karadima, G.
AU - Vekrellis, K.
AU - Koutsis, G.
JO - Translational Neuroscience
PY - 2020
VL - 431
TODO - null
SP - 34-39
PB - Elsevier Ireland Ltd
SN - null
TODO - 10.1016/j.neuroscience.2020.01.037
TODO - alpha synuclein;  dopamine receptor blocking agent;  serotonin noradrenalin reuptake inhibitor;  serotonin uptake inhibitor;  tetrabenazine;  alpha synuclein, adult;  Article;  CAG repeat;  clinical article;  controlled study;  disease burden;  disease duration;  enzyme linked immunosorbent assay;  female;  human;  Huntington chorea;  male;  priority journal;  protein blood level;  Unified Huntington Disease Rating Scale;  Huntington chorea;  Parkinson disease, alpha-Synuclein;  Humans;  Huntington Disease;  Parkinson Disease
TODO - Recent evidence suggests a potential role for mixed proteinopathies in the development of clinical manifestations in patients with Huntington's disease (HD). A possible cross-talk between mutant huntingtin and α-synuclein aggregates has been postulated. Serum α-synuclein has been evaluated as a potential biomarker in patients with Parkinson's disease (PD). We presently sought to investigate serum α-synuclein levels in 38 HD patients (34 symptomatic and 4 premanifest) and compare them to 36 controls. We found that α-synuclein was elevated in HD patients vs. controls (2.49 ± 1.47 vs. 1.40 ± 1.16, p = 0.001). There was no difference in α-synuclein levels between symptomatic vs. premanifest HD, nor between HD patients receiving medication vs. treatment-naïve. Furthermore, α-synuclein levels showed no correlation with CAG2, Unified HD Rating Scale (UHDRS) motor score, age, disease duration or disease burden score. Our results provide evidence for elevated serum α-synuclein in HD and lend support to further investigating the role of α-synuclein in this disorder. © 2020 IBRO
ER -